Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 7/20 | 0.50 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.50 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.50 |
| ▸ | RARB | P10826 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RARA | P10276 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | THRA | P10827 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4946744 | 0.88 | CYP4A11 (0.43) | PTGER4PTGER2PTGER3ALDH1A1MAPT | |
| SCHEMBL4943028 | 0.80 | PTGER4 (0.48) | PTGER4PTGER2PTGER3RARBMEN1 | |
| SCHEMBL5982493 | 0.80 | PTGER4 (0.48) | PTGER4PTGER2PTGER3RARBMEN1 | |
| SCHEMBL11636143 | 0.76 | RARB (0.53) | PTGER4PTGER2PTGER3RARBMEN1 | |
| SCHEMBL11546230 | 0.76 | RARB (0.56) | PTGER4PTGER2PTGER3RARBMEN1 | |
| SCHEMBL11549509 | 0.76 | RARB (0.56) | PTGER4PTGER2PTGER3RARBMEN1 | |
| SCHEMBL11549274 | 0.76 | RARB (0.56) | PTGER4PTGER2PTGER3RARBMEN1 | |
| SCHEMBL29127647 | 0.76 | RARB (0.56) | PTGER4PTGER2PTGER3RARBMEN1 | |
| SCHEMBL11636425 | 0.75 | RARB (0.52) | PTGER4PTGER2PTGER3RARBMEN1 | |
| SCHEMBL11547639 | 0.75 | RARB (0.57) | PTGER4PTGER2PTGER3RARBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465755-B2 | Hydrazide derivatives as prostaglandin receptors modulators | LABORATOIRES SERONO SA (CH) | 2008-12-16 | — | — | US | claimed |
| US-20070185191-A1 | Hydrazide derivatives as prostaglandin receptors modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-09 | — | — | US | claimed |
| US-7465755-B2 | Hydrazide derivatives as prostaglandin receptors modulators | LABORATOIRES SERONO SA (CH) | 2008-12-16 | — | — | US | disclosed |
| US-7465755-B2 | Hydrazide derivatives as prostaglandin receptors modulators | LABORATOIRES SERONO SA (CH) | 2008-12-16 | — | — | US | disclosed |
| US-7465755-B2 | Hydrazide derivatives as prostaglandin receptors modulators | LABORATOIRES SERONO SA (CH) | 2008-12-16 | — | — | US | disclosed |
| US-20070185191-A1 | Hydrazide derivatives as prostaglandin receptors modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-09 | — | — | US | disclosed |
| US-20070185191-A1 | Hydrazide derivatives as prostaglandin receptors modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-09 | — | — | US | disclosed |
| US-20070185191-A1 | Hydrazide derivatives as prostaglandin receptors modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-09 | — | — | US | disclosed |
| EP-1654219-A2 | HYDRAZIDE DERIVATIVES AS PROSTAGLANDIN RECEPTORS MODULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005012232-A2 | HYDRAZIDE DERIVATIVES AS PROSTAGLANDIN RECEPTORS MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185191-A1 | Hydrazide derivatives as prostaglandin receptors modulators | PTGIR, HPGDS, PGF | PTGER4 18/4885PTGER2 13/4885PTGER3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.